SCHEMBL5057002

SCHEMBL5057002

Cc1ccn2nc(-c3ccccc3)c(CO)c2n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
POLB P06746 2/20 0.44
HTR6 P50406 2/20 0.40
PTGS2 P35354 1/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GPR55 Q9Y2T6 1/20 0.38
GCGR P47871 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HTT P42858 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062727 0.86 HTR6 (0.40) POLBHTR6PTGS2MEN1KMT2A
SCHEMBL5062838 0.74 HTR6 (0.46) POLBHTR6PTGS2MEN1KMT2A
SCHEMBL5055450 0.73 SMN1; SMN2 (0.46) SMN1; SMN2POLBPTGS2MEN1KMT2A
SCHEMBL8354136 0.72 KDM4E (0.39) HTR6PTGS2GCGRKDM4E
SCHEMBL19209402 0.69 SMN1; SMN2 (0.63) SMN1; SMN2POLBMEN1KMT2APTGDR2
SCHEMBL13841918 0.69 KDM4E (0.49) SMN1; SMN2POLBHTR6PTGS2MEN1
SCHEMBL9752919 0.67 SMN1; SMN2 (0.43) SMN1; SMN2POLBMEN1KMT2AGCGR
SCHEMBL125610 0.65 SMN1; SMN2 (0.39) SMN1; SMN2POLBMEN1KMT2AKDM4E
SCHEMBL2077156 0.65 TDP1 (0.64) SMN1; SMN2POLBKMT2A
SCHEMBL19209419 0.65 PTGDR2 (0.56) SMN1; SMN2POLBPTGDR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP claimed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO claimed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed